DURHAM — BioCryst Pharmaceuticals (BCRX) on Tuesday reported a loss of $71.5 million in its fourth quarter.
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 38 cents.
The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 19 cents per share.
The drugmaker posted revenue of $79.5 million in the period, topping Street forecasts. Five analysts surveyed by Zacks expected $75 million.
Yet there were positive signs.
“Underlying demand from patients and physicians for ORLADEYO continues to be strong and consistent in the U.S. and our initial European launches are gaining traction with ORLADEYO now commercially available in 15 countries. All of this enables more and more patients to benefit from ORLADEYO, which is on a trajectory to achieve $1 billion in peak sales,” said Charlie Gayer, chief commercial officer of BioCryst.
ORLADEYO is an oral, once-daily treatment for prevention of Hereditary Angioedema (HAE) attacks.
For the year, the company reported that its loss widened to $247.1 million, or $1.33 per share. Revenue was reported as $270.8 million.
BioCryst shares have decreased 11% since the beginning of the year. The stock has decreased 46% in the last 12 months.
